Literature DB >> 6712865

Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.

E Iisalo, L Aaltonen.   

Abstract

The steady state serum levels of disopyramide and its metabolite, mono-N-dealkylated disopyramide (MND) were measured by gas-liquid chromatography in 40 patients receiving maintenance disopyramide treatment. The levels were mean 3.11 micrograms/ml +/- 0.28 (s.e. mean) and 0.9 micrograms/ml +/- 0.13 (s.e. mean), respectively. A radioreceptor assay was used for the quantitation of the anticholinergic activity of disopyramide and its metabolite in the same serum samples. The serum levels of anticholinergic activity varied between 0 and 6.7 ng/ml when measured as atropine equivalent (mean 1.88 +/- 0.26, s.e. mean, ng/ml). After a single oral dose of disopyramide the serum anticholinergic activity was, however, not detectable or very low. There was a significant correlation between disopyramide concentrations in serum and the serum anticholinergic activity (r = 0.655, P less than 0.001). No correlation was found between MND concentrations and the anticholinergic activity arguing against the role of MND causing antimuscarinic side effects. The affinity of MND for the muscarinic receptors in vitro was also lower than that of disopyramide.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6712865      PMCID: PMC1463360          DOI: 10.1111/j.1365-2125.1984.tb02348.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  The pharmacology of disopyramide.

Authors:  W G Nayler
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

2.  Antimuscarinic side-effects of disopyramide.

Authors:  E Iisalo; L Aaltonen
Journal:  Lancet       Date:  1983-04-30       Impact factor: 79.321

3.  Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite in plasma by gas-liquid chromatography.

Authors:  M L Aitio
Journal:  J Chromatogr       Date:  1979-12-01

4.  Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.

Authors:  C R Kumana; V S Rambihar; K Willis; R N Gupta; P H Tanser; J A Cairns; R A Wildeman; M Johnston; A L Johnson; M Gent
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

5.  Disopyramide concentrations in saliva.

Authors:  M L Aitio; R Virtanen; R Lammintausta
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-02

6.  The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.

Authors:  M L Aitio; H Allonen; J Kanto; R Mäntylä
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-05

7.  Application of radioreceptor assay of benzodiazepines for toxicology.

Authors:  L Aaltonen; M Scheinin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-03

8.  Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle.

Authors:  A M Grant; R J Marshall; S I Ankier
Journal:  Eur J Pharmacol       Date:  1978-06-15       Impact factor: 4.432

9.  Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment.

Authors:  T Nakahara; M Hirano; H Uchimura; M Saito; J S Kim; T Matsumoto; H Yokoo; M Shimomura; A Mukai
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects.

Authors:  L Tune; J T Coyle
Journal:  Arch Gen Psychiatry       Date:  1980-03
  10 in total
  1 in total

1.  A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers.

Authors:  J Longmore; J L Berry; E Szabadi; C M Bradshaw
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.